YO
JCR Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| IZCARGO® (pabinafusp alfa) | Mucopolysaccharidosis II (Hunter syndrome) | Approved |
| JR-141 (pabinafusp alfa) | Mucopolysaccharidosis II (Hunter syndrome) | Phase 3 |
| JR-171 (lepunafusp alfa) | Mucopolysaccharidosis I (with CNS involvement) | Phase 1/2 |
| JR-441 | Sanfilippo syndrome Type A (MPS IIIA) | Preclinical |
| JR-161 | Tay-Sachs/Sandhoff disease | Preclinical |
Leadership Team at JCR Pharmaceuticals
SA
Shin Ashida
Representative Director, President & CEO
KA
Katsuhiko Asano
Director, Senior Managing Executive Officer
HY
Hiroshi Yagi
Director, Senior Managing Executive Officer, Head of Quality & Manufacturing
KS
Kazutaka Shimoda
Director, Managing Executive Officer, Head of Research & Development
YK
Yoshikazu Kato
Director, Managing Executive Officer, Head of Corporate Strategy & Administration
HK
Hironori Kawasaki
Director, Managing Executive Officer, Head of Sales & Marketing
KO
Koji Okamoto
Director, Executive Officer
TS
Toshihiro Shibayama
Director, Executive Officer, Head of Business Development
MA
Masanori Aoki
Director, Executive Officer
YM
Yoshihiro Matsumura
Corporate Auditor